Current cancer immunotherapies are primarily predicated on αβ T cells, with a stringent
dependence on MHC-mediated presentation of tumour-enriched peptides or unique …

γδ T-cells directly recognize and kill transformed cells independently of HLA-antigen
presentation, which makes them a highly promising effector cell compartment for cancer …

The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

Abstract γδ T cells play uniquely important roles in stress surveillance and immunity for
infections and carcinogenesis. Human γδ T cells recognize and kill transformed cells …

Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Aberrant CD4+ T cell reactivity against intestinal microorganisms is considered to drive
mucosal inflammation in inflammatory bowel diseases. The disease-relevant microbial …

The potential of cancer immunotherapy relies on the mobilization of immune cells capable of
producing antitumour cytokines and effectively killing tumour cells. These are major …

Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …

Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with limited response to
cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor …

The recent advances in the field of immuno-oncology have dramatically changed the
therapeutic strategy against advanced malignancies. Bispecific antibody-based …